The International Menopause Society - SFOG

More documents

Recommendations

Info

WHI: HT use and mortality by age at baseline Age HR 95% CI 50 – 59 0.70 0.51 – 0.96 60 – 69 1.05 0.87 – 1.26 70 – 79 1.14 0.94 – 1.37 Rossouw J et al, JAMA 2007;297:1465
Postmenopausal Hormone <strong>The</strong>rapy: an Endocrine <strong>Society</strong> Scientific Statement Santen RJ,Allred DC,Ardoin SP et al. J Clin Endocrinol Metab 2010;95 (Suppl 1):S1-S66
Page 1 and 2: HRT idag och i morgon: mot lägre d
Page 3 and 4: jan-00 jul-00 jan-01 jul-01 jan-02
Page 5: Djup förtroendekris Risker och sä
Page 9 and 10: ERT vs HRT Progestin related side e
Page 11 and 12: No uterus no problem !
Page 14 and 15: Progesterone and progestins can rea
Page 16 and 17: Secreted VEGF in T47-D cells in res
Page 18 and 19: Breast stimulation a class effect
Page 20 and 21: HRT utan bröstpåverkan Är det m
Page 22 and 23: change in density from different pr
Page 24 and 25: Vaginal Maturation Index Placebo 10
Page 26 and 27: Mean number NUMBER OF MODERATE TO S
Page 28 and 29: Mean breast density (%) Mammographi
Page 30: Testosterone addition inhibits estr
Page 33 and 34: Tibolone and BC risk in healthy wom
Page 35 and 36: MLS 10 µg LNG/day Mirena 20 µg LN
Page 37 and 38: Raloxifene
Page 39: BZA 20 mg/ CEE 0.45 mg a 2 year RCT
Page 42 and 43: Mammary Gland Branching in Ducts fr
Page 44 and 45: Options for breast safety Regim VMS

The International Menopause Society - SFOG

Create successful ePaper yourself

Delete template?

Save as template?